Bosutinib
규격
380843-75-4CAS 번호
700-455-1EC 번호
4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrileIUPAC 명칭
C26H29Cl2N5O3화학식
530.4 g/mol분자량
Bosutinib; 380843-75-4; SKI-606; SKI 606; 4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile; 4-((2,4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile; 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile; SK-606; 4-((2,4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methyl-1-piperazinyl)propoxy)-3-quinolinecarbonitrile; 5018V4AEZ0; CHEBI:39112; DTXSID10861568; 3-Quinolinecarbonitrile, 4-((2,4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methyl-1-piperazinyl)propoxy)-; bosutinibum; uglysycpd2; RefChem:58901; DTXCID40207910; L01XE14; 4-Anilinobenzo(g)quinoline-3-carbonitrile; 700-455-1; 943-866-3; 4-Anilino-3-quinolinecarbonitrile; Bosutinib (SKI-606); BOSULIF; SKI606; 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile; Bosutinib (USAN); Bosutinib [USAN]; MFCD07367846; 4-(2,4-dichloro-5-methoxyphenylamino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile; BOSUTINIB ISOMER 1; CHEMBL288441; C26H29Cl2N5O3; SKI-606); 4-(2,4-dichloro-5-methoxy-anilino)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile; Bosutinib [USAN:INN]; NCGC00241107-01; UNII-5018V4AEZ0; Bosutinib API; Bosutinib (Standard); Bosutinib,SKI-606; BOSUTINIB [INN]; BOSUTINIB [MI]; BOSUTINIB [VANDF]; PF-5208763; BOSUTINIB [MART.]; EC 700-455-1; BOSUTINIB [WHO-DD]; Bosutinib (SKI-606)?; MLS006011212; SCHEMBL158390; BDBM4552; GTPL5710; orb1225150; orb1310890; orb3141310; Bosutinib Isomer 1, Free Base; Bosutinib, >=98% (HPLC); SCHEMBL29350234; SCHEMBL29428159; EX-A391; UBPYILGKFZZVDX-UHFFFAOYSA-N; GLXC-90178; HMS2043A22; HMS3244A03; HMS3244A04; HMS3244B03; HMS3651C03; HMS3672K11; HMS3743E09; HMS5079M03; K00615a; EBC-11336; HB1323; HY-10158R; NSC765694; NSC799367; SK 606; AKOS015902521; AC-2413; CCG-208129; CS-0118; DB06616; FB19002; NSC-765694; NSC-799367; PB30881; SDCCGSBI-0646926.P001; NCGC00241107-03; NCGC00241107-05; NCGC00241107-06; AS-11064; HY-10158; SMR002530350; NS00002757; S1014; SW220197-1; D03252; AB01565836_03; EN300-7565041; F794031; Q894611; SR-01000941572; SR-01000941572-1; BRD-K99964838-001-01-0; BRD-K99964838-001-06-9; BRD-K99964838-001-11-9; BRD-K99964838-001-12-7; Z2216885221; 3-QUINOLINECARBONITRILE, 4-((2,4-DICHLORO-5-METHOXYPHENYL)AMINO)-6-METHYL-1-PIPERAZINYL)PROPOXY)-; 4-(2,4-Dichloro-5-methoxy-phenylamino)-6-methoxy-7-[3-(4-methyl-piperazin-1-yl)propoxy]quinoline-3-carbonitrile동의어
Bosutinib 함유 제품
BOSUTINIB ZENTIVA 500 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFGBOSUTINIB ZENTIVA 400 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFGBOSUTINIB ZENTIVA 100 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFGBOSUTINIB STADA 500 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFGBOSUTINIB STADA 400 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFGBOSUTINIB STADA 100 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFGBOSUTINIB DR. REDDYS 500 COMPRIMIDOS RECUBIERTOS CON PELICULA EFGBOSUTINIB DR. REDDYS 400 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFGBOSUTINIB DR. REDDYS 100 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFGBOSUTINIB ZENTIVA 500 mg, comprimé pelliculéBOSUTINIB ZENTIVA 400 mg, comprimé pelliculéBOSUTINIB ZENTIVA 100 mg, comprimé pelliculé
1/3 페이지
Bosutinib 판매 기업
ML
MSN LaboratoriesIndiaRP
Reddy Pharma Iberia S.A.SpainLC
LEAP CHEM CO., LTD.1/2 페이지